drugset / Trial / NCT03568656
Study to Evaluate CCS1477 in Advanced Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
Timeline
- Start
- 2018-07-23
- Primary completion
- 2025-07-06
- Completion
- 2025-07-06
Publications
- Caligiuri M, Williams GL, Castro J, Battalagine L, Wilker E, Yao L, Schiller S, Toms A, Li P, Pardo E, Graves B, Azofeifa J, Chicas A, Herbertz T, Lai M, Basken J, Wood KW, Xu Q, Guichard SM. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer. Target Oncol. 2023 Mar;18(2):269-285. doi: 10.1007/s11523-023-00949-7. Epub 2023 Feb 24.
- Eickhoff N, Bergman AM, Zwart W. Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer. Endocrinology. 2022 Oct 11;163(11):bqac153. doi: 10.1210/endocr/bqac153.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 500 mg | — |
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | — |
| Subject | Darolutamide | Other / unclassified | 300 mg | — |
| Subject | Enzalutamide | Other / unclassified | 40 mg | — |
| Subject | Inobrodib | Small molecule | — | Oral |
| Subject | Olaparib | Small molecule | 150 mg | — |
| Background | Prednisolone | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | — |